Pinnacle Wealth Management Advisory Group LLC Boosts Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Key Points

• Pinnacle Wealth Management Advisory Group LLC increased its investment in Regeneron Pharmaceuticals by 46.8%, acquiring a stock position valued at $969,000.
• A significant majority of the company's stock, approximately 83.31%, is held by institutional investors and hedge funds, reflecting strong interest from large finance entities.
• Recent analyst ratings show a mix of outlooks, with a variety of price targets; Regeneron's average target price is set at $837.61, indicating a "Moderate Buy" recommendation.

Pinnacle Wealth Management Advisory Group LLC grew its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 46.8% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,528 shares of the biopharmaceutical company's stock after purchasing an additional 487 shares during the quarter. Pinnacle Wealth Management Advisory Group LLC's holdings in Regeneron Pharmaceuticals were worth $969,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the stock. Capital International Investors lifted its holdings in Regeneron Pharmaceuticals by 41.6% during the 4th quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock worth $3,373,859,000 after purchasing an additional 1,390,534 shares during the last quarter. GAMMA Investing LLC grew its position in Regeneron Pharmaceuticals by 89,825.0% during the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after acquiring an additional 814,713 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its holdings in Regeneron Pharmaceuticals by 63.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock worth $1,485,527,000 after buying an additional 810,144 shares during the period. Pacer Advisors Inc. lifted its holdings in Regeneron Pharmaceuticals by 2,296.9% during the 1st quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock worth $258,366,000 after buying an additional 390,374 shares during the period. Finally, Assenagon Asset Management S.A. lifted its holdings in Regeneron Pharmaceuticals by 171.0% during the 1st quarter. Assenagon Asset Management S.A. now owns 481,389 shares of the biopharmaceutical company's stock worth $305,311,000 after buying an additional 303,785 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

Analysts Set New Price Targets

REGN has been the topic of a number of recent analyst reports. Canaccord Genuity Group reissued a "buy" rating and issued a $850.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, July 23rd. The Goldman Sachs Group dropped their price objective on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating on the stock in a research note on Wednesday, April 30th. Wall Street Zen downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 1st. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price target on the stock. in a research note on Friday. Finally, Morgan Stanley reaffirmed an "overweight" rating on shares of Regeneron Pharmaceuticals in a research note on Friday. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $837.61.

Regeneron Pharmaceuticals Trading Up 0.1%

Shares of NASDAQ REGN traded up $0.44 during midday trading on Friday, reaching $545.90. The company had a trading volume of 1,037,122 shares, compared to its average volume of 1,115,399. Regeneron Pharmaceuticals, Inc. has a one year low of $476.49 and a one year high of $1,211.20. The company has a quick ratio of 4.03, a current ratio of 4.93 and a debt-to-equity ratio of 0.09. The firm's fifty day moving average price is $538.64 and its 200-day moving average price is $604.99. The stock has a market cap of $58.93 billion, a PE ratio of 13.89, a price-to-earnings-growth ratio of 2.08 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. During the same quarter in the prior year, the firm earned $9.55 EPS. The firm's revenue for the quarter was down 3.7% on a year-over-year basis. On average, equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, June 6th. Investors of record on Tuesday, May 20th were issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Tuesday, May 20th. Regeneron Pharmaceuticals's payout ratio is currently 8.96%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.